

*genzyme*

Legal Department FAX Number (508) 872-5415

FACSIMILE MESSAGE

FAX RECEIVED

JUN 21 2002

GROUP 1600

TO: United States Patent and Trademark Office  
Attn: Examiner Anjum I. Rishi  
Group Art Unit: 1632  
Facsimile No: 703-308-4242

FROM: Elizabeth Lassen  
Registration No. 31,845



OFFICIAL

DATE: June 20, 2002

RE: Preliminary Amendment  
USSN: 09/826,609  
Our Reference: GA0150C

TOTAL NUMBER OF PAGES INCLUDING THIS PAGE: 7

Please confirm receipt of the attached Preliminary Amendment (3 sheets) to facsimile # 508-872-5415

Notice of Confidentiality

This transmission is intended only for the addressee(s) listed above and may contain information that is confidential and privileged. If you are not the intended recipient or an agent responsible for delivering to the intended recipient, you are hereby notified you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If you have received this transmission in error, please telephone us immediately and return the original message to us by mail. Thank you.

Genzyme Corporation, Metrowest Place, 15 Pleasant Street Connector,  
P.O. Box 9322, Framingham, MA 01701-9322

FAX RECEIVED

JUN 21 2002

GROUP 1600

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile  
transmitted to the Patent and Trademark Office

on June 20, 2002.

Date



Signature

Taryn Antalek

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this  
certificate must identify each submitted paper.

A Preliminary Amendment (3 sheets); and Fee Transmittal (in duplicate).

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Applicable for use through 10/31/2002. OMB 0851-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

## Complete If Known

Application Number	09/828,609
Filing Date	April 5, 2001
First Named Inventor	ROBERTS, Bruce
Examiner Name	Anjum I. Rishi
Group / Art Unit	1632
Attorney Docket No.	GA0150C

TOTAL AMOUNT OF PAYMENT (\$ 120

### METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 07-1074

Deposit Account Name GENZYME CORPORATION

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) during the pendency of this application  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

### FEE CALCULATION

#### 1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Release filing fee	
114	180	214	80	Provisional filing fee	

SUBTOTAL (1)

(\$ 0

#### 2. EXTRA CLAIM FEES

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
25	6		2	18	36
			1	84	84
					0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	Release independent claims over original patent
110	18	210	9	Release claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$ 120

\*\*or number previously paid, if greater; For Reissues, see above

### FEE CALCULATION (continued)

#### 3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	820*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	480	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or release)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17 (q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
148	740	248	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
189	900	189	900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$ 0

### SUBMITTED BY

Name (Print/Type)	Registration No. (Attorney/Agent)	Telephone
Elizabeth Lassen	31,845	508-270-2553
Signature		Date
<i>Elizabeth Lassen</i>		6/20/02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Patent  
Our Docket: GA0150C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9/B

In re Application of:	)	Art Unit: 1632
Roberts et al.	)	
Serial No.: 09/826,609	)	Examiner: Anjum I. Rishi
Filed: April 5, 2001	)	
For: GENES DIFFERENTIALLY EXPRESSED	)	
IN CANCER CELLS TO DESIGN	)	
<u>CANCER VACCINES</u>	)	

Assistant Commissioner for Patents  
Washington, D.C. 20231

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED VIA FACSIMILE TO EXAMINER ANJUM I. RISHI, GROUP ART UNIT 1632, FACSIMILE NUMBER 703-308-4242	
<i>[Signature]</i> Date: <i>June 20, 2002</i>	<i>[Signature]</i> Signature of person faxing correspondence

**PRELIMINARY AMENDMENT**

Sir:

Further to the **RESPONSE TO RESTRICTION REQUIREMENT** mailed June 6, 2002, please enter the following amendments to the claims in advance of examination of the instant application.

**CLAIMS**

Please add new claims 25-26 as follows:

25. (New) A method to identify a putative cancer therapeutic comprising the steps of:

a) identifying a first polynucleotide which is expressed at a higher level in a target cancer cell as compared with a control non-cancer cell;

B1